Treating ALL during COVID-19

Bookmark and Share
Published: 20 Oct 2020
Views: 1676
Prof Mohamad Mohty - Saint-Antoine hospital, Paris, France

Prof Mohamad Mohty speaks to ecancer about how the COVID-19 pandemic has affected the treatment of ALL.

He says that patients inflicted by haematological malignancies are in an immuno-suppresive state and are highly susceptible to COVID.

Their age can often make them more vulnerable too.

He says treatment of these patients should hence be done keeping all these factors in mind and should not be delayed.

He further highlights a few treatment modalities for different types of ALL and the risks attached to it.

In the end, he talks about how the problems arising by COVID-19 can be managed safely and promptly through appropriate management.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.